AstraZeneca reinforces commitment to protecting the most vulnerable from serious infectious diseases at IDWeek 2023
Real-world data from INFORM study demonstrate increased risk of severe COVID-19 outcomes among all individuals with immunocompromising conditions and highlight need for additional protection. FluMist Quadrivalent data support the potential for a self-administered influenza vaccine to expand access to an important tool for prevention. AstraZeneca will showcase new preclinical, clinical and real-world data across its Vaccines & Immune Therapies portfolio at the 12th annual IDWeek conference 11-15 October, reinforcing the important role of long-acting antibodies and vaccines to protect at-